中邮证券发布研报称,siRNA药物可精准沉默致病蛋白,优势显著,递送系统为核心技术。海外巨头基于GalNAc肝递送平台,针对心血管靶点的药物已进入收获期。国内企业百花齐放,成为全球重要参与者,与MNC合作频发。中邮证券主要观点如下:siRNA药物机制优势突出,递送为核心技术相较于传统小分子和生物药,siRNA药物为代表的核酸疗法可精准沉默致病蛋白,高效降解且作用时间长,目前已成为新药开发热门方向。...
Source Link中邮证券发布研报称,siRNA药物可精准沉默致病蛋白,优势显著,递送系统为核心技术。海外巨头基于GalNAc肝递送平台,针对心血管靶点的药物已进入收获期。国内企业百花齐放,成为全球重要参与者,与MNC合作频发。中邮证券主要观点如下:siRNA药物机制优势突出,递送为核心技术相较于传统小分子和生物药,siRNA药物为代表的核酸疗法可精准沉默致病蛋白,高效降解且作用时间长,目前已成为新药开发热门方向。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.